Skip to main content

RAPID #RISK #ASSESSMENT: #EBOLA VIRUS DISEASE, DRC (#WHO, September 19 '25)

 


{Summary}

Overall risk and confidence

Overall risk

-- National: High 

-- Regional: Moderate   

-- Global: Low   

Confidence in available information 

-- National: Moderate

-- Regional: Moderate

-- Global: Moderate


Risk statement

On 1 September 2025, WHO received an alert from the Ministry of Health of the Democratic Republic of the Congo (DRC) regarding suspected cases of Ebola virus disease (EVD) in the Bulape Health Zone, Kasai Province, DRC. 

The first currently known suspected EVD case was admitted to the Bulape General Reference Hospital on 20 August 2025 and reported to have died five days later (25 August 2025).

This is a 34-year-old female patient with a 34-week gestational age who presented with fever, bloody diarrhoea, followed by anal, oral, and nasal haemorrhage, vomiting, and asthenia

She reportedly died on 25 August 2025, with a clinical picture of multiple organ failure. 

Two of the contacts of this first case (a midwife and a laboratory technician) also developed similar symptoms and died a few days later.  

As of 4 September 2025, a total of 28 suspected cases, including 15 deaths (case fatality ratio: 54 %) had been reported from the Bulape health zone (Bulape, Bulape COM and Dikolo) and Mweka health zone. 

Among deaths, four are health care workers.  

In addition, 20% of the suspected cases are aged under 15 years

Five blood samples and one swab were collected from six suspected cases from the three health areas and arrived today at the National Public Health Laboratory (INRB) in Kinshasa for confirmation testing.

A crisis committee has been activated at the local and provincial levels, risk communication and active surveillance activities are underway, all cases are isolated, Infection Prevention and Control (IPC) measures are being implemented, isolation and contact tracing are underway, and patients are receiving intravenous medications, including ceftriaxone and metronidazole

The INRB confirmed Ebola virus (EBOV), Orthoebolavirus zairense species was detected through RTPCR assays, including GeneXpert, on 3 September.    

At national level, the risk is considered high due to:  

Information gaps on the cases, including the first case, particularly: 

-- the date of symptom onset, 

-- their therapeutic itinerary, 

-- the potential number of contacts within the community, and 

-- epidemiological links between cases does not allow an assessment as to the extent of the outbreak. Similar alerts have been reported from this location/region in the past few months.  

Most of the cases recorded so far in this health zone live in the Health Areas with a high population density and mobility. This could accelerate disease transmission within the community.  

The last EVD outbreak in this health zone, Bulape, was in 2007, 18 years later, the capacities required for the response to a potential EVD outbreak may not exist.  

So far, in addition to Bulape health zone, the epicentre of the outbreak, suspected cases are being reported in the neighbouring district of Mweka showing a potential geographic extension of the outbreak.   

Bulape has a large market every Friday, attracting people from the surrounding villages. The city of Mweka borders a health district in the province of Kasai-Central (Bena Leka). Furthermore, population movements between Bulape and Tshikapa, the capital city of Kasai province, are frequent as part of trading activities.  Tshikapa city is considered as a regional market hub receiving populations from neighbouring provinces.  

At the regional level the risk is moderate due to the proximity of Bulape to Tshikapa city, the capital city of Kasai province and the Angolan border (approximately 100 to 200 kilometres depending on the nearest border crossing point) as well as population movement between Bulape and Tshikapa then Tshikapa and Angola.  

At the global level, the risk is low

(...)

Source: World Health Organization, https://www.who.int/publications/m/item/who-rapid-risk-assessment---ebola-virus-disease--democratic-republic-of-the-congo-v.1

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...